The downregulation of hepcidin in HCC can affect HCC pathogenesis by promoting the growth of cancerous cells by activating the cyclin-dependent kinase-1/STAT3 (CDK1/STAT3) pathway (Shen et al. 2019). The gene discussed is HAMP; the disease is hepatocellular carcinoma.